# Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

> **NCT03770000** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rhizen Pharmaceuticals SA** · enrollment: 33 (actual)

## Conditions studied

- T Cell Lymphoma

## Interventions

- **DRUG:** Tenalisib
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT03770000
- **Lead sponsor:** Rhizen Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-12
- **Primary completion:** 2021-05-14
- **Final completion:** 2021-05-14
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03770000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03770000, "Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03770000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*